Accueil   Diary - News   All news VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE

This partnership concerns the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics

 

 

  • Nestlé Health Science’s global reach and metabolic diseases focus expected to support TOTUM-63 development and global commercialization;
  • Strategic partnership secures funding for the latest clinical development phase until the obtention of health claims from American and European Authorities;
  • Deal is structured around an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million and tiered royalties on net sales;
  • Agreement also includes TOTUM-63 supply to Nestlé Health Science representing an additional source of revenue.

 

 

La Rochelle, 5 February 2020 (5:40 PM CET) – VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics.

 

 

Read the press release